Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

nd penalties of $38.1 million.

At December 31, 2007 net deferred tax liabilities of $56.7 million (December 31, 2006: net deferred tax asset of $261.0 million) were recognized. Shire has moved from a net deferred tax asset to a net deferred tax liability position primarily because of the recognition of a deferred tax liability of $394.8 million at acquisition in respect of intangible assets acquired with New River, offset by deferred tax asset of $46.7 million relating to New River's net operating loss carry forwards.

Equity in earnings of equity method investees

Net earnings of equity method investees of $1.8 million were recorded for the year to December 31, 2007 (2006: $5.7 million). This comprised earnings of $6.5 million from the 50% share of the anti-viral commercialization partnership with GSK in Canada (2006: $6.2 million), offset by losses of $4.7 million being the Company's share of losses in the GeneChem, AgeChem and EGS Healthcare Funds (2006: losses of $0.5 million).

FAS123R compensation cost

The total FAS123R charge for the year was $75.2 million (2006: $43.0 million). Excluding a catch-up charge of $29.2 million there was a 7% increase in the FAS123R charge over 2006.

The catch up charge relates to options issued by Shire in 2005 under the 2000 Executive Scheme. This charge arises as a result of the strong growth in revenue and profits which the Company has generated in Q4 2007. This growth has in turn caused the Company to revise its original assumptions on which the FAS123R charge was based.

Financial Information

Unaudited US GAAP results for the year to December 31, 2007

Consolidated Balance Sheets

December 31,

December 31,

2007 2006


'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Aug. 21, 2014  China Cord Blood Corporation (NYSE: ... to release financial results for the first quarter of ... market close in the US.  The ... ET on Friday, August 29, 2014 to discuss its ... Company,s recent developments, followed by a question and answer ...
(Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
(Date:8/21/2014)... August 21, 2014 Gallus ... contract development and manufacturing organization (CMO) announced today ... Inc., an oncology company focused on the development ... to manufacture the anti-prostate specific membrane antigen (PSMA) ... candidate. Under the agreement the antibody will ...
(Date:8/21/2014)... August 21, 2014 On Wednesday of last ... to use Redox Signaling molecules, became available for purchase in ... , "The way that RENU 28 works is, if you ... down of the rate of cellular renewal within your body. ... increasing of that rate of cellular renewal. What RENU 28 ...
Breaking Biology Technology:China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3RENU 28 Skin Care Now Available in Australia and New Zealand 2
... China , May 18 /PRNewswire-Asia/ -- Ningbo ... was officially put into operation, successfully being used in ... steel slag as an absorbent,instead of lime or other ... of lime agents, the replacement reduces SO2 emissions by,more ...
... CLEVELAND, Ohio , May 18, 2010 Simbionix USA Corporation,the ... and the healthcare industry, is proud to,report that their ANGIO Mentor virtual ... Societies in April 2010 for,the training and certification of vascular ... , , ...
... ... with ultra-fine finishing capabilities , ... (PRWEB) -- The increased miniaturization of medical devices such as surgical instruments ... the integral items that have helped to facilitate the use of miniaturized medical devices ...
Cached Biology Technology:TAIJI Announces Official Operation of Its Sintering FGD Project for Tangshan 2Simbionix ANGIO Mentor Plays Important Role in Physician Training and Certification 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 2Ultra-Fine Metal Tubing Smoothes the Way for Miniaturized Medical Devices 3
(Date:8/20/2014)... in in this image of the Para and Mato ... most likely intentionally set in order to deforest the ... stand of trees where the land is thereafter converted ... of forestland to farms, ranches, or urban use. The ... the Amazon Rainforest in the middle of the image ...
(Date:8/20/2014)... the Oklahoma Medical Research Foundation a five-year, $14.5 million ... bacteria,s effects on humans. , For 10 years, ... studied the human immune response to anthrax bacteria as ... original funding came soon after anthrax-laced letters killed five ... attacks of Sept. 11, 2001. , The long-term ...
(Date:8/20/2014)... seawater signals a relaxing trip to the shore. But ... comes with an environmental hitch. When certain sunblock ingredients ... become toxic to some of the ocean,s tiniest inhabitants, ... animals. Their study appears in the ACS journal ... David Snchez-Quiles point out that other than staying indoors, ...
Breaking Biology News(10 mins):$14.5 million grant awarded to continue anthrax studies 2
... shows that prenatal health care professionals are concerned about ... providing effective counseling. Rates of excessive weight gain ... adverse health outcomes for mothers and children, have increased ... care providers agree that weight gain is an important ...
... Palo Alto, CATo engineer better, more productive crops ... look at how the sensor-laden membranes surrounding cells ... interact with the environment and neighboring cells to ... about how proteins interact with these protective structures. ...
... to three-dimensional puzzles, Rubik,s Cube pales in comparison with ... Gordon and collaborators Chuck DeMets of the University of ... in Pasadena, Calif., have just put the finishing touches ... of the relative movements of the interlocking tectonic plates ...
Cached Biology News:Prenatal health-care providers inconsistent in weight-gain counseling 2Cracking the plant-cell membrane code 2Tectonics: Precision is hallmark of 20-year study 2Tectonics: Precision is hallmark of 20-year study 3
... tube luminometer provides the sensitivity and versatility ... Advanced digital photon counting with selected photomultipliers ... spectral demands. Equipped with up to 2 ... for reporter gene assays as well as ...
... convenient, and efficient native protein concentration following ... spin column to make handling easy. The ... which were electro-eluted in their native condition. ... high binding capacity fo all pH values. ...
MAb to HLA, Class II-DR+DP Dry Ice: No Preservative: NaN3 Availability When Not in Inventory: 14-21 Business Days...
Cell Culture Flask, nontreated polystyrene...
Biology Products: